While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Sidra Medicine, a member of Qatar Foundation, has established a gene therapy centre to treat rare genetic diseases such as ...
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Qatar Tribune on MSN2d
Qatar: Sidra establishes Gene Therapy Center for rare genetic diseasesThe announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programmes ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
GlobalData on MSN3d
Roche reports positive topline outcomes from DMD treatment trialRoche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback